EV and pembrolizumab doubling PFS and OS in 1st line UC compared to chemotherapy @NEJM
Uromigos
2,565 posts
Uromigos
@Uromigos
The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
- Efortumab Vedotin and pembrolizumab showing response rates of 71% (n=45) in front line urothelial cancer #esmo19. Amazing data. Patients will want this. Tom
- A summary of the ADC session at #UromigosLive24 with @apolo_andrea @shilpaonc @PGrivasMDPhD @tompowles1 & @kalasri3
- 🎯 Announcing the Eurasia team for the Uromigos cup 🏆 November 7th and 8th - Nashville with Cristina Suarez. Current score is Eurasia =1 vs North America= 0 from the 🎯 darts competition!! @montypal & Americas got 51 ❤️ ‘likes’ in 10 days. Can Eurasia get more??
00:00 - 🎯 the Eurasia team are now 6-0 ahead for the Uromigos cup 🏆 @MichvdHeijden is part of the team November 7th and 8th in Nashville. Here he is in beautiful Amsterdam among the canals 🇳🇱 🇳🇱 🇳🇱 🇳🇱 🇳🇱. Hearts ♥️ points. @OncoAlert
- 🧵#UromigosLive #ProstateCancer Poll: Emerging therapeutic approaches for the treatment of mHSPC ‼️👇POLLS TO FOLLOW‼️ (1/3) 👇
- Paper of the month: @JoshMeeks develops 5 subgroups based on RNA signatures to predict response a PD(L)1 in urothelial cancer (figure bellow). Multiple mechanisms of response/resistant creates a complex picture which Josh simplifies . anchor.fm/the-uromigos/e…
- While the Americas 🇨🇦 🇺🇸 are 0-6 down in the Uromigos cup 🏆, with team 🇦🇺 🇦🇺 Australia 🇦🇺 🇦🇺 🦘 🦘 winning the last photo competition . Here @montypal if the USA 🇺🇸 🇺🇸 🇺🇸 capital. 3 points available for the final photo !!! ❤️ =points @OncoAlert @montypal @DrChoueiri
- 🧵#UromigosLive #ProstateCancer Poll: You've seen data for mHSPC doublet trials👇 from #CHAARTED #Stampede #Latitude #TITAN #ARCHES #ENZAMET and triplet trials 👇from #PEACE1 #ARASENS. No trial compared ADT + ARAT versus ADT + ARAT + Docetaxel. ‼️POLLS TO FOLLOW‼️ (1/6)
- Prostate cancer poster highlights #asco22 . Which patients benefit from docetaxel chemotherapy @ChrisSweens1
00:00 - @brian_rini and @tompowles1 have launched a new website, Uromigos.org, featuring podcasts, videos, Uromigos Live annual meeting material and much more! Visit soon for #GU23 content. @montypal @shilpaonc @PGrivasMDPhD @neerajaiims @drenriquegrande @DrChoueiri
00:00 - 🧵#UromigosLive #ProstateCancer: Most successful strategies for developing anticancer combination Rx commonly adhere to the following👉1⃣ Distinct MOA 2⃣ Significant single agent activity3⃣ Non-overlapping toxicities ➡️Ex. BEP for germ cell tumors. mHSPC following the example‼️
- @JoshMeeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb
- 1st line bladder cancer, what just happened? #nashvillelive Was nivo/cis data expected? Who shouldn’t get EV pembro? How much does maintenance avelumab help? What next now EV/pembro is standard treatment? @DrRosenbergMSK @MattGalsky @shilpaonc 👉m.youtube.com/watch?v=oHqLHn…
